Drugs / AVID200
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03895112 | Feb 2019 → May 2022 | myelofibrosis, primary myelofibrosis | John Mascarenhas | Completed | No outcome recorded |
| Phase 1 | NCT03834662 | Jan 2019 → Feb 2020 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03831438 | Jan 2019 → Jun 2020 | diffuse cutaneous systemic sclerosis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVID200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03895112 ↗ |
| Action | Inhibit | “novel inhibitor of TGF-β ligands” NCT03831438 ↗ |
| Modality | Protein / enzyme biologic | “A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ” NCT03834662 ↗ |
| Route | Intravenous | “Intravenous infusion of AVID200 Q2 weeks for 3 doses” NCT03831438 ↗ |